Impact Therapeutics Gets Positive EMA Opinion for Ovarian Cancer Drug

MT Newswires Live

Yesterday

Impact Therapeutics (HKG:7630) said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Senaparib as a maintenance treatment for advanced ovarian, fallopian tube and primary peritoneal cancer.

The recommendation is based mainly on results from the Phase III FLAMES trial, the company said in a Friday Hong Kong bourse filing. The drug will now be submitted to the European Commission for a final decision. If approved, Senaparib will be authorized for marketing across European Union member states and European Economic Area countries.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2668928894"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2668928894\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2668928894?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2668928894","market":"nz","top_or_hot":-1,"title":"Impact Therapeutics Gets Positive EMA Opinion for Ovarian Cancer Drug","media":"MT Newswires Live","content":"<html><body><p> Impact <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:7630) said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Senaparib as a maintenance treatment for advanced ovarian, fallopian tube and primary peritoneal cancer.</p><p>The recommendation is based mainly on results from the Phase III FLAMES trial, the company said in a Friday Hong Kong bourse filing. The drug will now be submitted to the European Commission for a final decision. If approved, Senaparib will be authorized for marketing across European Union member states and European Economic Area countries.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Impact Therapeutics Gets Positive EMA Opinion for Ovarian Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImpact Therapeutics Gets Positive EMA Opinion for Ovarian Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-18 19:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Impact <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:7630) said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Senaparib as a maintenance treatment for advanced ovarian, fallopian tube and primary peritoneal cancer.</p><p>The recommendation is based mainly on results from the Phase III FLAMES trial, the company said in a Friday Hong Kong bourse filing. The drug will now be submitted to the European Commission for a final decision. If approved, Senaparib will be authorized for marketing across European Union member states and European Economic Area countries.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2668928894","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2668928894","pubTimestamp":1789730092,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Impact Therapeutics  said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Senaparib as a maintenance treatment for advanced ovarian, fallopian tube and primary peritoneal cancer.The recommendation is based mainly on results from the Phase III FLAMES trial, the company said in a Friday Hong Kong bourse filing. The drug will now be submitted to the European Commission for a final decision. If approved, Senaparib will be authorized for marketing across European Union member states and European Economic Area countries.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK4139":"生物科技","07630":"英派药业-B","BK4007":"制药","BK4539":"次新股","LENZ":"Therapeutics","EPV":"ProShares UltraShort MSCI Europe"},"translate_title":"Impact Therapeutics 卵巢癌药物获得 EMA 积极意见","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPV":0.88,"LENZ":1.5,"07630":1},"content_text":"Impact Therapeutics (HKG:7630) said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Senaparib as a maintenance treatment for advanced ovarian, fallopian tube and primary peritoneal cancer.The recommendation is based mainly on results from the Phase III FLAMES trial, the company said in a Friday Hong Kong bourse filing. The drug will now be submitted to the European Commission for a final decision. If approved, Senaparib will be authorized for marketing across European Union member states and European Economic Area countries.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}